EUVIMEDEUVIMED entdecken
Crossref

Strong diagnostic performance of plasma ptau217 for CSF biomarker-defined young-onset Alzheimer disease in a diagnostically heterogeneous clinical cohort

Dhamidhu Eratne, Qiao-Xin Li, Courtney Lewis, Christa Dang, Matthew J Y Kang, Jasleen Grewal, Samantha Loi, Mark Walterfang, Andrew H Evans, Charles B Malpas, Steve Pedrini, Ralph Martins und 9 weitere

Journal of Neurology · 2025-01 · 272 (1)

DOI: 10.1007/s00415-024-12732-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neurology, online erschienen am 12.12.2024. Verfasst von Dhamidhu Eratne und 20 weiteren Autor:innen. Beteiligte Einrichtung: Neuropsychiatry, Royal Melbourne Hospital, 300 Grattan St, Parkville, VIC, 3052, Australia. deratne@unimelb.edu.au. Hauptthemen laut MEDLINE: Alzheimer Disease, tau Proteins, Biomarkers, Amyloid beta-Peptides. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: We investigated diagnostic utility of phosphorylated tau 217 and 181 (ptau217, ptau181), glial fibrillary acidic protein (GFAP), amyloid beta 42 and 40 (Aβ42, Aβ40), and neurofilament light (NfL) to distinguish biomarker-defined Alzheimer disease (AD) from non-AD conditions, in a heterogenous clinical cohort of younger people. METHODS: Plasma biomarkers were analysed using ultrasensitive technology, and compared in patients with CSF Alzheimer disease profiles (A+T+) to other CSF profiles (Other). RESULTS: Seventy-nine patients were included, median age 60.8 years: 16 A+T+, 63 Other. Ptau217, ptau181, GFAP were significantly elevated in A+T+ compared to Other (3.67 vs 1.12 pg/mL, 3.87 vs 1.79 pg/mL, 189 vs 80 pg/mL, respectively). ptau217 distinguished AD from Other with 90% accuracy (88% specificity, 100% sensitivity). ptau217 also demonstrated strong diagnostic performance for clinically diagnosed AD. CONCLUSIONS: Plasma ptau217 has strong diagnostic performance in distinguishing CSF biomarker-defined AD in a clinically relevant, younger cohort of people with symptoms, adding further weight for a simple diagnostic blood test for AD as a cause of a patient's symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer Diseasetau ProteinsBiomarkersAmyloid beta-PeptidesNeurofilament ProteinsHumansFemaleMaleMiddle AgedCohort StudiesAgedGlial Fibrillary Acidic ProteinPeptide FragmentsAge of OnsetAdultPhosphorylationSensitivity and Specificity

Stichwörter der Autor:innen

Alzheimer’s diseaseBiomarkerDementiaDiagnosisptau217

Substanzen

tau ProteinsBiomarkersAmyloid beta-PeptidesNeurofilament Proteinsneurofilament protein LGlial Fibrillary Acidic ProteinPeptide Fragmentsamyloid beta-protein (1-42)GFAP protein, humanamyloid beta-protein (1-40)

Autor:innen und Institutionen

  • Neuropsychiatry, Royal Melbourne Hospital, 300 Grattan St, Parkville, VIC, 3052, Australia. deratne@unimelb.edu.au.
  • Department of Psychiatry, University of Melbourne, Grattan St, Parkville, Melbourne, VIC, 3052, Australia. deratne@unimelb.edu.au.
  • The Florey Institute, 30 Royal Parade, Parkville, VIC, 3052, Australia. deratne@unimelb.edu.au.
  • The Florey Institute, 30 Royal Parade, Parkville, VIC, 3052, Australia.
  • Department of Psychiatry, University of Melbourne, Grattan St, Parkville, Melbourne, VIC, 3052, Australia.
  • National Ageing Research Institute, 34-54 Poplar Rd, Parkville, VIC, 3052, Australia.

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Eratne, D., Li, Q. X., Lewis, C., Dang, C., Kang, M. J. Y., Grewal, J., Loi, S., Walterfang, M., Evans, A. H., Malpas, C. B., Pedrini, S., Martins, R., Chatterjee, P., Zetterberg, H., Blennow, K., Berkovic, S. F., Santillo, A. F., Collins, S., Masters, C. L., …, & MiND Study Group (2025). Strong diagnostic performance of plasma ptau217 for CSF biomarker-defined young-onset Alzheimer disease in a diagnostically heterogeneous clinical cohort. Journal of Neurology, 272(1). https://doi.org/10.1007/s00415-024-12732-3

Vancouver

Eratne D, Li QX, Lewis C, Dang C, Kang MJY, Grewal J, et al. Strong diagnostic performance of plasma ptau217 for CSF biomarker-defined young-onset Alzheimer disease in a diagnostically heterogeneous clinical cohort. Journal of Neurology. 2025;272(1). doi:10.1007/s00415-024-12732-3

BibTeX
@article{Eratne2025,
  author = {Eratne, Dhamidhu and Li, Qiao-Xin and Lewis, Courtney and Dang, Christa and Kang, Matthew J Y and Grewal, Jasleen and Loi, Samantha and Walterfang, Mark and Evans, Andrew H and Malpas, Charles B and Pedrini, Steve and Martins, Ralph and Chatterjee, Pratishtha and Zetterberg, Henrik and Blennow, Kaj and Berkovic, Samuel F and Santillo, Alexander F and Collins, Steven and Masters, Colin L and Velakoulis, Dennis and MiND Study Group, MiND Study Group},
  title = {Strong diagnostic performance of plasma ptau217 for CSF biomarker-defined young-onset Alzheimer disease in a diagnostically heterogeneous clinical cohort},
  journal = {Journal of Neurology},
  year = {2025},
  volume = {272},
  number = {1},
  doi = {10.1007/s00415-024-12732-3}
}
Kostenlos starten →